Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HCT After Nonmyeloablative Conditioning for Severe Systemic Sclerosis
NCT01047072Phase 2Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Primary completion
- Sep 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic hematopoietic stem cell transplantation in systemic sclerosis (SSc), sponsored by Fred Hutchinson Cancer Center. Status: withdrawn.
02
Drugs
allogeneic hematopoietic stem cell transplantation
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT01047072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01047072.